The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis

BJU Int. 2008 Sep;102(8):952-7. doi: 10.1111/j.1464-410X.2008.07732.x. Epub 2008 May 15.

Abstract

Objectives: To assess the prognostic significance of lymphovascular invasion (LVI) on clinical outcomes in patients with transitional cell carcinoma of the bladder treated with radical cystectomy (RC).

Patients and methods: We retrospectively evaluated a prospectively maintained and authorised cystectomy database; the presence or absence of LVI was determined by pathological examination of the RC specimen. Cox regression analysis and Kaplan-Meier tables were developed to evaluate the contribution of LVI to clinical outcomes.

Results: In all, we analysed 356 patients treated with RC and urinary diversion between 1988 and 2006, with a mean follow-up of 45.6 months. Of these patients, 242 (68%) had no evidence of LVI in the RC specimen, whereas 114 (32%) had LVI. Patients with LVI tended to present with higher pathological stage; 84 (74%) had pT3 or pT4 disease. On univariable analysis the presence of LVI conferred a significant risk for decreased overall, cancer-specific and recurrence-free survival (P < 0.001); the mean values for LVI-negative patients were 96.8, 157.4, and 135.0 months, respectively, vs LVI-positive patients, whose survival times were 52.3, 82.7 and 75.2 months, respectively. The multivariable analysis showed significant independent risk for cancer-specific and overall survival for patients who were LVI-positive and had no lymph-node metastases. The hazard ratios (95% confidence interval) were 1.63 (1.06-2.51, P < 0.026) and 1.81 (1.06-3.08, P < 0.03) for overall and disease-specific survival, respectively.

Conclusions: The presence of LVI in the pathological RC specimen confers significant independent risk for reduced bladder cancer-specific and overall survival. This variable could be used to prospectively stratify patients who would benefit from adjuvant chemotherapy.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Transitional Cell / mortality
  • Carcinoma, Transitional Cell / pathology*
  • Carcinoma, Transitional Cell / therapy
  • Chemotherapy, Adjuvant
  • Cystectomy / methods*
  • Epidemiologic Methods
  • Female
  • Humans
  • Lymphatic Metastasis / pathology
  • Male
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Prognosis
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy

Substances

  • Antineoplastic Agents